We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
- Authors
Attard, Gerhardt; Reid, Alison H M; Yap, Timothy A; Raynaud, Florence; Dowsett, Mitch; Settatree, Sarah; Barrett, Mary; Parker, Christopher; Martins, Vanessa; Folkerd, Elizabeth; Clark, Jeremy; Cooper, Colin S; Kaye, Stan B; Dearnaley, David; Lee, Gloria; de Bono, Johann S
- Abstract
Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 28, p4563
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.9749